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Abstract 
While the current epigenetic-drug development is still largely restricted to target DNA 
methylome, emerging evidence indicates that histone methylome is indeed another 
major epigenetic determinant for gene expression and frequently deregulated in acute 
myeloid leukaemia (AML). The recent advances in dissecting the molecular 
regulation and targeting histone methylome in AML together with the success in 
developing lead compounds specific to key histone methylation modifying enzymes 
have revealed new opportunities for effective leukaemia treatment. In this article, we 
will review the emerging functions of histone methyltransferases (HMTs) and histone 
demethylases (HDMs) in AML, especially MLL rearranged leukaemia. We will also 
examine recent pre-clinical and clinical studies that show significant promises of 
targeting these histone methylation modifying enzymes for AML treatment. 
Introduction 
Although intensive chemotherapy combined with transplantation of haematopoietic 
stem cells have considerably improved the outcomes in certain subgroups of younger 
leukaemia patients, acute myeloid leukaemia (AML) as the most common type of 
acute leukaemia in adults remains highly fatal and around 80% of patients aged over 
60 succumb to the disease or the highly toxic treatment regimens 1, 2. AML is a 
heterogeneous group of diseases that can be further classified into different subgroups 
according to their distinctive genetic mutations with variable prognostic significances. 
In spite of the large arrays of mutations reported in AML, most of them specifically 
affect transcription factors or key components of epigenetic machinery. Importantly, 
chimeric fusions that are believed to be the initiating events in translocation 
leukaemia almost always involve transcription/epigenetic factors 3. Among them is 
the Mixed Lineage Leukaemia Gene (MLL) that associates with a very poor prognosis 
and treatment resistant 4. Similar mutational profiles affecting transcriptional and 
epigenetic machinery have also been reported in normal karyotype AML (NK-AML), 
where DNMT3A and NPM are found to be the early events and persist during 
relapses 5-7, consistently indicating the importance of transcriptional deregulation in 
AML pathogenesis. In spite of our advance in understanding the genetics of AML, 
very little has been translated into the clinics and we are still using the same highly 
toxic and rather ineffective chemotherapies developed over a half-century ago. 
Therefore, there is an urgent need to identify novel venues for more potent and 
effective drug development to tackle this formidable disease. While development of 
small molecule inhibitors to transcription factors remains technically challenging, the 
recent discoveries of critical function of epigenetic modifying enzymes with 
structurally rigid motifs and/or catalytic domains in AML pathogenesis have fuelled 
the enthusiasm to target these intractable oncogenic events. In this review, we will 
focus on some of the latest pre-clinical and clinical development of epigenetic therapy 
in AML in particular those involve MLL gene rearrangements. 
Epigenetic therapies targeting DNA methylation and histone acetylation in AML 
The term epigenetics refers to alternations of gene expression that are 
inheritable after cell division without any changes in DNA sequence 8. In addition to 
DNA methylation, an increasing number of epigenetic modifications on histones 
including acetylation, methylation and ubiquitination have been identified and are 
frequently deregulated in AML 9, 10, resulting in repression of tumour suppressor 
genes (TSGs) and/or activation of oncogenic pathways 11. Aberrant DNA methylation 
and histone acetylation are two most ancient and better-characterized epigenetic 
changes. DNA methylation, leading to gene silencing, is prevalent in cancers 
including leukaemia, and has been the target for cancer therapy since the FDA 
approval of DNA methyltransferase (DNMT) inhibitors (DNMTi), azacytidine and 
decitabine for the treatment of myelodysplastic syndrome (MDS) and certain AML 12. 
Although AML patients aged over 65 years who treated with DNMTi did not show 
significantly longer overall survival (OS) as compared with conventional care 
regimen, azacytidine and decitabine displayed safety and better clinical efficacy in 
patients with unfavourable cytogenetics or myelodysplasia-related changes, indicating 
that they may be preferable therapies for these “difficult-to-treat” AML population 13, 
14. In addition to DNMTi, a number of pan histone deacetylase (HDAC) inhibitors 
(HDACi) inducing chromatin remodelling and re-expression of TSGs, are also 
designed and utilized in AML treatment 15. While single-agent therapy was reported 
only having modest clinical activity, combination of HDACi with DNMTi (decitabine, 
complete remission (CR): 31%) or with Ara-c (cytarabine, CR: 78%, OS: 82 weeks) 
in clinical trials appeared to be synergistic and profoundly improved responses 16, 17. 
While these early endeavours on heterogeneous myeloid malignancies have 
demonstrated the safety and potential therapeutic values of targeting epigenetic 
machinery in clinical settings, it also urges the need of better understanding of the 
epigenetic regulation and exploring novel critical targets for effective AML treatment. 
To overcome the problems associated with genetic heterogeneity that may in part 
account for the poor efficacy of DNMTi or HDACi in the clinics, recent studies 
focusing on systematic analyses of leukaemia carrying chimeric transcription factors 
or specific mutations affecting histone methylation modifying enzymes provide 
important insights and novel tractable targets for epigenetic therapies in AML. 
The role of histone methyltransferases (HMTs) in AML 
Depending on the position and nature of the methylated residues, histone 
methylation can have positive as well as negative impacts on gene expression 18. 
Histone methylation features epigenetic modification in which lysine and arginine 
residues can be mono-(me1), di-(me2) or even tri-(me3) methylated (for lysine only). 
In general, methylation of histone 3 lysine 4 (H3K4), lysine 36 (H3K36), lysine 79 
(H3K79) as well as asymmetric dimethylation of histone 4 arginine 3 (H4R3) 
activates gene expression; whereas methylation on other sites like histone 3 lysine 9 
(H3K9), lysine 27 (H3K27), histone 4 lysine 20 (H4K20) and symmetric 
dimethylation of H4R3 associate with transcription repression 18, 19. H3K4me3 and 
H3K27me3 that define bivalent marks are predominately mediated by two master 
epigenetic regulators, Trithorax group (TrxG) proteins with HRX/MLL as the 
founding member and Polycomb group (PcG) proteins with EZH1/2 as the catalytic 
subunits of polycomb repressor complex 2 (PRC2) in mammalian cells 20.  Intriguing, 
the key components of both TrxG and PcG complexes are frequently mutated in AML.   
Investigating the association of chromosome 7q abnormalities in myeloid 
malignancy has revealed an important role of EZH2 in leukaemogenesis. EZH2 
regulates expression of numerous genes critical for stem cell renewal by mediating a 
H3K27 methylation 21.  EZH2 mutations were found in 9 of 12 patients with 
chromosome 7q acquired uniparental disomy, and the majority of EZH2 mutations 
resulted in loss of its H3K27 methyltransferae activity 22, which is in contrast with its 
gain of function mutation in B-cell lymphoma 23. Deletion of EZH2 was able to 
induce a MDS-like disease in a mouse model, suggesting the tumour suppressor 
function of EZH2 in certain myeloid malignancies 24-26. On the other hand, loss-of-
function mutations of ASXL1, another PcG protein, are usually associated with 
unfavourable OS and poor CR rate in AML 27. While its molecular function in 
leukemic transformation is still unclear, depletion of ASXL1 showed loss of PRC2 
mediated H3K27 trimethylation and led to upregulation of HOXA genes including 
HOXA5 and HOXA9. On the contrary, overexpression of ASXL1 resulted in a global 
increase of H3K27 me2/3 and suppression of HOXA genes and cell growth. ASXL1 
can interact with EZH2 in human leukemic cells, and loss of ASXL1 resulted in 
displacement of PRC2 from HOXA loci 28. ASXL1 may also collaborate with BAP1, 
loss of which led to a MDS-like syndrome in a mouse model, to deubiquitinate 
H2AK119 at PcG targets 29, 30. Haematopoietic-specific knockout of ASXL1 
profoundly impaired cell differentiation and induced myeloid dysplasia and erythroid 
dysplasia in knockout mice. Furthermore, transplantation of ASXL1-null LSK cells or 
bone marrow (BM) cells into recipient mice strikingly caused lethal myelodysplastic 
disorder 31. In addition to ASXL1, JARID2 has also been identified as an essential 
cofactor in promoting PRC2 recruitment to downstream targets. An acquisition of 
JARID2 mutation showed a positive correlation with disease progress from MDS to 
AML 32. Together, these studies reveal the critical role of EZH2 and PRC2 in 
malignant haematopoiesis. 
MLL as a master transcriptional and epigenetic regulator containing a number 
of functional domains including AT hook and CXXC motifs at the N-terminal and the 
C-terminal SET domain, which mediates specific H3K4 methylation, is predisposed 
to abnormal gene rearrangements resulting in a highly aggressive form of leukaemia 
33. As a result of chromosomal translocations, chimeric MLL-fusions resulting from 
replacement of C-terminal region of MLL including the SET domain by various 
fusion partners such as AF4/6/9/10, ELL and ENL can form macromolecular 
complexes through recruitment of a cohort of cofactors including super elongation 
complex (SEC) (e.g., positive transcription elongation factor b (p-TEFb), MLL fusion 
partners such as AF4 family and AF9/ENL family), polymerase associated factor 
complex (PAFc), BRD3/4, MENIN and key histone methyltransferases (HMTs) (e.g., 
DOT1L, PRMT1) to activate gene expression programmes crucial for the 
transformation 18 (Fig.1A). Identification of key aberrantly recruited HMTs by MLL-
fusions provide the first hint of their involvement in human cancer 34.  
DOTlL is the only lysine methyltransferase (KMT) known to be responsible 
for H3K79 methylation in human. Aberrant recruitment of DOT1L specifically 
associates with an abnormally high level of H3K79me2 on promoters and gene bodies 
of MLL targets in MLL rearranged leukaemia. The remarkable correlation of 
H3K79me2 and MLL targets has been referred to as a special epigenetic lesion in 
MLL leukaemia, implying the essentiality of H3K79 methylation for MLL-driven 
transcription 35. Inactivation of DOT1L profoundly suppressed expression of MLL 
translocation-associated genes (e.g., HOXAs and MEIS1) and leukaemia development 
36-40 (Fig. 1A). Direct fusion of DOT1L to MLL was sufficient to activate 
transcription of HOXAs 39. Loss of DOT1L resulted in reduction of cell growth, 
increased differentiation and apoptosis of MLL-AF9 leukaemic cells, indicating its 
potential as a target for AML therapy 38. On the other hand, PRMT1 is the founding 
member of protein arginine methyltransferases (PRMTs) that mediates arginine 
methylation on both histone (H4R3me2a) and non-histone substrates (e.g., 
transcription factors and splicing factors). Identification of its essential function in 
MLL leukaemia had also provided the first evidence of PRMT involvement in human 
cancer 41. PRMT1 recruitment is required for a subset of MLL (MLL-EEN and MLL-
GAS7) and non-MLL (MOZ-TIF2 and AML1-ETO) leukaemia 41-43. Its inhibition 
resulted in specific transcriptional and leukaemic suppression in MLL-rearranged and 
MOZ-TIF2 leukaemia 42. Silence of PRMT1with an shRNA approach attenuated the 
level of H4R3me2a and gene expression of HOXA9 and MEIS1, thus leading 
suppression of leukaemogenesis of MOZ-TIF2 and MLL-GAS7. More recently, a 
functional link between PRC2 and MLL leukaemia had also been proposed.  EZH2 
and EED, two core components of PRC2, had been shown to be required for MLL 
leukaemia, although the underlying mechanisms remain largely unknown 44, 45.  While 
these studies highlight the importance of HMTs in MLL leukaemia, emerging 
evidence also reveals an equally important role of histone demethylases (HDMs) that 
counteract the functions of HTMs in modulating the epigenetic regulation of gene 
expression in both normal and cancer settings.   
The role of histone demethylases (HDMs) in AML 
 Protein methyltransferases (including KMTs and PRMTs indicated in the 
previous section) mediate methylation on specific amino acid residues, which can 
however be erased by HDMs mostly lysine demethylases (KDMs). Based on their 
catalytic mechanisms, KDMs can be divided into two major subgroups. The first 
family including KDM1A and KDM1B is also known as lysine specific demethylase 
(LSD), consisting of FAD-dependent amine oxidase, which can only remove mono- 
and di-methyl marks 46. On the contrary, the second KDM family contains JmjC 
domain (JMJD), which relies on α-ketoglutarate, Fe(II)  and oxygen as cofactors to 
mediate demethylation of mono-, di- and even tri-methyl-lysine residues 47. JMJD 
demethylases consist of more diverse family members and can be further divided into 
7 subfamilies from KDM2 to KDM8 according to their other structurally conserved 
domains, like PHD and Tudor domains, which may also bear crucial functions in 
recognizing/reading the histone marks 19.   
 KDMs can be found differentially expressed in various cancers including 
leukaemia, and cooperate with transcription factors to activate or repress gene 
expression. LSD1 is over-expressed in MLL leukaemia and seems to play a crucial 
role in sustaining the oncogenic transcriptional programmes mediated by MLL-
fusions via an unknown mechanism (Fig. 1B). LSD1 suppression by an shRNA 
approach led to a reduction of mouse MLL leukaemic stem cells (LSCs) 48. While this 
study suggests a requirement of H3K4 demethylase for MLL leukaemia, a recent 
report revealed an opposite role of H3K4 demethylase KDM5B that negatively 
regulated MLL LSC (Fig. 1C) 49. In this study, H3K4me2/3 but not H3K79me2 were 
critical for MLL LSC, and H3K4 methylation levels reduced during differentiation.  
Suppression of KDM5B significantly promoted disease progression, whereas its 
overexpression inhibited MLL leukaemia. While the reasons underlying the different 
results need further investigations, LSD1 on the other hand underpins retinoic acid 
receptor (RARa)-driven repression of myeloid differentiation associated genes in 
AML through decreasing the level of H3K4me2 50.  These results may suggest a more 
generic role of H3K4 methylation in AML pathogenesis, which may not be specific to 
MLL leukaemia. Other members of KDMs including KDM2B and JMJD1C also 
implicate in AML pathogenesis. H3K36me2 demethylase KDM2B that silences 
p15 expression was sufficient to transform haematopoietic progenitors in vitro, and its 
depletion significantly impaired HOXA9/MEIS1 driven leukaemogenesis and self-
renewal of leukaemic stem cells 51. H3K9 demethylase JMJD1C was identified as a 
crucial factor for the maintenance of AML expressing MLL-AF9 in an shRNA 
functional screen (Fig.1B). Depletion of JMJD1C inhibited cell growth and 
leukaemogenesis of MLL-AF9 cells by triggering apoptosis 52. JMJD1C had also been 
recently implicated in AML1-ETO 53 and HOXA9-mediated leukaemias 54. JMJD1C 
was identified as a coactivator in AETFC, a complex formed by AML1-ETO, where 
JMJD1C maintained low level of H3K9me2, hence enhancing gene expression of 
AML1-ETO targets. Knockdown of JMJD1C compromised the ability of AML1-ETO 
to inhibit cell differentiation and impaired colony formation 53. JMJD1C also 
interacted with HOXA9 to modulate the downstream genes critical for self-renewal of 
leukaemic stem cells. Loss of JMJD1C profoundly affected leukaemic transformation 
driven by HOXA9, indicating yet another KDM family member with a more generic 
function in AML pathogenesis 54. 
Crosstalk between HMTs and HDMs in AML 
Although the above reports have directly implicated individual HMT and 
HDM in AML pathogenesis, their mode of actions and underlying mechanisms 
remain largely unknown. Recent studies exploring the functional crosstalk between 
HMTs and HDMs have shed lights into the intricate molecular regulation of aberrant 
histone methylome in AML. It has been demonstrated that the chromatin localization 
of SIRT1, a H3K9 deacetylase, and SUV39H1, a H3K9 methyltransferase, may be 
disrupted by DOT1L (Fig. 2A). After inhibition of DOT1L, SIRT1 and SUV39H1 
bound to MLL targets such as HOXA7 and MEIS1 and exerted their function to 
establish a heterochromatin-like state, in which the level of H3K9me2 but not 
H3K79me2 was kept considerably high. Deletion of SIRT1 or SUV39H1 significantly 
desensitised MLL-AF9 leukaemic cells to DOT1L inhibition, whereas 
pharmacological activation of SIRT1 by SRT1720 strikingly improved the in vivo 
efficacy of EPZ4777, a DOT1L inhibitor, demonstrating a critical function of this 
crosstalk in regulating DOT1L inhibitor sensitivity 55. To search for novel epigenetic 
regulators that cooperate with PRMT1 in AML pathogenesis, KDM4C was identified 
to specifically interact with MLL-fusions and MOZ-TIF2 to remove H3K9me3 
repressive mark 42. Together with PRMT1, KDM4C co-regulated the epigenetic 
programmes for transcriptional deregulation and cellular transformation by increasing 
the H4R3me2a active mark but attenuating H3K9me3 repressive mark on MLL 
downstream targets such as HOXA9 (Fig. 2B). Similar to PRMT1, shRNA-mediated 
suppression of KDM4C resulted in repression of MLL downstream gene expression 
programmes, attenuation of leukaemogenesis and a significant improvement of OS in 
mouse and humanized models, revealing the requirement of the presence of both 
epigenetic modifying enzymes for the oncogenic functions of MLL-fusions. Since 
KDM4C binds to MLL N-terminus region, KDM4C is also required for leukaemia 
induced by other MLL-fusions independent on PRMT1, suggesting a much broader 
function of KDM4C in maintaining aberrant epigenetic networks in MLL leukaemia. 
Interestingly, a recent study suggested a potential redundant function among KDM4 
family members in AML using a tamoxifen inducible knockout approach 56.  
Although characterization of the actual genotype on Kdm4c knockout leukaemic cells 
was not performed, genetic escape from in vivo deletion of Kdm4 family seems to be 
a common theme in all the resultant leukaemia with genotyping results, which was in 
line with the requirement of an unusually high dose of tamoxifen to achieve even in 
vitro deletion.  Nevertheless, these studies consistently indicate critical functions of 
KDM4 family in acute leukaemogenesis. 
The role of KDM in treatment response 
In addition to disease progression, KDM has also been implicated in 
governing treatment response in acute promyelocytic leukaemia (APL) driven by 
RARa-fusions. APL is the only AML subgroup with a well-established target therapy 
where All Trans Retinoic Acid (ATRA) can induce transcriptional de-repression and 
leukaemic differentiation.  In spite of success in identifying repressor complexes 
associated with RARa-fusions, the identity of the activator being recruited by the 
fusions upon ATRA treatment had remained elusive. To search for such a regulator, 
PHF8 (KDM7B), a H3K9 demethylase, was found to specifically interact with RARa-
fusion proteins to remove H3K9me2 repressive mark upon ATRA treatment 57 (Fig. 
3). ATRA treatment results in a conformation change of RARa-fusions, leading to 
dissociation of corepressors such as HDAC and PRC2. PHF8 acts as a critical sensor 
for ATRA treatment response, which is dependent on both the enzymatic activity and 
the phosphorylation status of two critical serine residues of PHF8 that partly 
determine its chromatin localization. Genetic or pharmacological activation of PHF8 
sensitized ATRA-refractory cells to the treatment whereas its suppression conferred 
resistance to APL cells. These findings for the first time directly implicate the activity 
of KDM in governing AML treatment responses, and reveal a novel therapeutic venue 
to overcome treatment resistant 58. In addition to PHF8, LSD1 is also involved in the 
repressive machinery of RAR-fusions (Fig. 3). Inhibition of LSD1 could increase the 
level of H3K4me2 on the promoters of myeloid-differentiation associated genes and 
triggered ATRA-therapeutic response in non-APL AML. While ATRA exhibited little 
effects in non-APL AML, combination of ATRA and the LSD1 inhibitor TCP 
remarkably initiated cell differentiation of non-APL AML and reduced colony 
formation and engraftment of AML 50. 
Histone methylome as an emerging therapeutic target 
Given the critical functions of histone methylome in AML, the first HMT 
inhibitor targeting DOT1L, EPZ4777 59 and its second-generation derivative, 
EPZ5676 60 have been developed and tested for suppressing MLL leukaemia. Both 
compounds showed selective inhibitory effects on H3K79 methylation and cells 
bearing MLL-fusions (Table1). Continuous infusion of DOT1L inhibitors 
significantly prolonged the OS in murine models with MLL leukaemia 59, 60, leading 
to the first clinical trial of HMT inhibitors in AML. However, the poor 
pharmacokinetic characteristics of the DOT1L inhibitors may limit their clinical 
development 60, and can be partly responsible for the rather modest clinical responses 
in their early trial results. On the other hand, a PRMT1 inhibitor, AMI-408 could also 
significantly extend disease latency and OS in mouse models carrying MLL-GAS7 
fusion or MOZ-TIF2 42. Similarly to DOT1L inhibitors, the efficacy of PRMT1 
inhibitors in leukaemia suppression was far inferior to those by genetic or shRNA 
approaches, indicating the need to improve the pharmacokinetics of these early phase 
inhibitors. Studies also reported prolonged OS and reduced tumour burden in MLL-
AF9 leukaemia model by targeting of a H3K27 methyltransferase EZH2. The EZH2 
inhibitor DZNep triggered apoptosis of AML cells through reactivating TXNIP, 
leading accumulation of reactive oxygen species (ROS) 61. Depletion of EZH2 or 
pharmacological inhibition of EZH1/2 by a small molecule UNC1999 up-regulated 
PRC2 target genes such as p16 and p19 in MLL leukaemic cells 62, 63. There are also 
highly effective EZH2 inhibitors such as GSK126 and EPZ5687 for diffuse large B-
cell lymphoma 64, 65.  GSK126 and stapled hydrocarbon peptide targeting EZH/EED 
interaction have been tested in parallel and shown strong suppression of in vitro MLL 
leukaemia cell growth, although their in vivo efficacy has yet to be demonstrated 66.  
Similarly, while very limited in vivo data has been shown, a monoamine 
oxidase (MOA) inhibitor, tranylcypromine (TCP) alone or in combination with 
ATRA has been used to suppress LSD1 activity in MLL 48 or non-MLL leukaemia in 
vitro 50 (Table1), respectively. A TCP derivative, GSK2879552 has entered phase I 
clinical trials for the treatment of relapsed AML (ClinicalTrials.gov identifier: 
NCT02177812), however TCP exhibited severe toxicity at efficacious doses in 
preclinical models, so it is possible that the TCP may result in broad toxicity, 
especially in central nervous system 67. Recently, a non-MOA inhibitor SP2509 with 
similar efficacy but lower general toxicity as compared with TCP was developed 
(Table1). SP2509 blocked the interaction between LSD1 and the co-repressor 
CoREST, thus leading to a permissive increase in H3K4me3 on target genes such as 
p21, p27 and CCAAT/enhancer binding protein. SP2509 was able to effectively 
suppress colony formation, induced cell differentiation and triggered apoptosis of 
AML cells with mutant NPM1 but not MLL-fusions 68. However, while inhibition of 
LSD1 showed a significant efficacy in a mouse xenograft model, it could only 
consistently translate into extended OS when it was a combination with PS, a pan-
HDAC inhibitor 68. It is noted that all the above epigenetic targets in particular 
DOT1L and LSD1 are absolutely essential for normal development and 
haematopoietic stem cells, which will likely limit the application of effective dose in 
patients and therefore a combination approach with lower dose may be beneficial. In 
contrast, KDM4C is largely dispensable for normal development and its complete 
deletion does not lead to any significant phenotypes in the mouse model. Consistently, 
an early phase KDM4C inhibitor, SD70 displayed an excellent therapeutic effect on 
AML expressing MOZ-TIF2 and MLL-fusions 42 (Table 1). Pharmacological 
inhibition of KDM4 effectively attenuated leukaemogenesis in vivo and extended OS 
in both mouse and humanized models with primary human MLL leukaemia. 
Remarkably, SD70 is quite well tolerated and has limited toxicity in these preclinical 
models, highlighting its therapeutic potentials for AML treatment.  
Prospective 
Transcriptional deregulation plays the key role in acute leukaemogenesis and 
probably treatment responses. The emerging functions of various epigenetic 
modifying enzymes of histone methylome in AML pathogenesis have provided 
unique opportunities to target this group of dismal disease, in which its treatment 
regime has not really changed for decades. In addition to the histone mark writers and 
erasers, it is also possible to target readers that are essential to recognize these specific 
histone marks for aberrant gene expression and transformation.  It has been proposed 
that WDR5, one of main components of MLL complexes essential for MLL histone 
methyltransferase activity, recognises H3K4me and presents the K4 side chain for 
further methylation by MLL 49, 69, 70. Blocking MLL1-WDR5 interaction by a small 
molecule inhibitor MM-401 specifically reduced levels of H3K4me at HOXA loci, 
induced myeloid differentiation and triggered apoptosis of mouse MLL-AF9 
leukaemic cells 71. In addition to WRD5 family, significant progress has been made to 
target bromodomain that recognizes acetyl-lysine marks. One of the best examples is 
the potential targeting of BRD family in MLL leukaemia. Genetic or pharmacological 
inhibition of BRD3/4 by I-BET151 (GSK1210151A) or JQ1 led to suppression of 
BCL-2, Myc and CDK6 in leukaemic cells, and displayed outstanding efficacy 
against mouse and human leukaemia cells driven by MLL-fusions in vitro and in vivo 
(Table1) 72, 73. Although rapid development of drug resistant in pre-clinical models in 
part due to activation of canonical Wnt/b-catenin signalling may pose a threat for 
effective treatments by BRD inhibitors 74, 75, these studies provide an important proof-
of-principle data showing the feasibility of targeting protein-protein interaction 
involved in epigenetic regulation for leukaemia treatment. Similar principles will 
likely be applicable to other readers involved in histone methylome such as 
chromodomain and PHD domain. Future studies in dissecting the molecular 
regulation of critical histone methylome writers, readers and erasers will open up a 
promising venue for development of next generation effective AML treatments. 
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Figure 1. Roles of HDMs and KDMs in MLL-driven transcription 
(A) MLL-fusion complexes are assembled ) by recruiting a body of important 
components (SEC, PAFc, MENIN and LEDGF ) to target and facilitate expression of 
crucial leukaemogenic genes, such as HOXs, MEIS and MEF2C, where HMTs 
(DOT1L, PRMT1 and MLL) are involved to add active methyl marks (H3K79me2/3, 
H4R3me2a, H3K4me3), respectively. BRD4, a histone mark reader,  is essential for 
the recruitment of MLL-fusions. (B) In addition to enrichment of active marks, KDMs 
(e.g., KDM4C, JMJD1C) on the other hand remove repressive marks (H3K9me3) to 
underpin the active status.  Although LSD1 has been suggested to remove 
H3K4me1/2 marks in MLL leukaemia, its relevance to leukaemia suppression is still 
largely unknown.  (C) KDM5B negatively regulates MLL target genes through 
demethylation of H3K4me3 active mark. Black arrows indicate methylation, whereas 
bent red arrows represent demethylation.  
Figure 2. Crosstalk between HMTs and HDMs in MLL-driven transcription 
(A) When DOT1L is recruited by MLL fusions, it confers H3K79me2 active mark, 
which may further expel SUV39H1 and SIRT1, hence leading to a reduction in 
H3K9me2 repressive mark but an increase in H3K9ac activation mark. (B) After 
binding to MLL fusions and MOZ-TIF2, PRMT1 and KDM4C cooperate to maintain 
the activation of MLL-driven transcription by conferring a high level of H4R3me2a 
high but a low level of H3K9me3 repressive mark. 
Figure 3. Roles of KDMs in ATRA therapeutic response 
PML-RARa forms a repressor complex with RXRa, HDACs and PRCs to inhibit 
expression of myeloid differentiation associated genes. In non-APL, LSD1 is also 
recruited to further remove H3K4me2/1, contributing to a more stable repressive 
status (not shown in figure). ATRA treatment results in a conformational change of 
PML-RARa, leading to dissociation of HDACs and PRCs, and recruitment of 
phosphorylated PHF8 to confer transcriptional activation. Activation of PHF8 by 
okadaic acid (OKA) may sensitise refractory APL cells to ATRA treatment. 
 
